US FDA’s Stein ‘Excited’ About Real-World Evidence, Rare Disease Endpoint Pilot Programs
Executive Summary
Head of Office of New Drugs highlights programs being established under PDUFA VII that could help overcome obstacles in drug development.
You may also be interested in...
Real-World Evidence: US FDA Urged To Leverage Prior Validation Work and Regulatory Experience
In comments on FDA guidance on electronic health records and medical claims, Duke-Margolis Center suggests a certification process for validated datasets, while data companies request the agency do more to publicize the experience to date with RWE in regulatory submissions.
Real-World Data: FDA Urged To Distinguish Between Electronic Health Records And Medical Claims
Comments on September draft guidance seek more attention to differences between the two types of data sources; pharma firms said they may not always have access to all the information the US FDA wants to see about a particular data source, and they seek additional flexibility on validation.
Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office
US FDA commissioner-nominee Califf calls for streamlining clinical trial bureaucracy, as well as open access to clinical data.